

Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Randall C. Starling, M.D., M.P.H., F.A.C.C.

Committee: Circulatory System Devices Panel of the Medical Devices Advisory Committee

Meeting Dates: August 22-23, 2023

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda items on August 22, 2023 to discuss, make recommendations, and vote on information regarding a premarket approval application (PMA) for the ReCor Paradise Ultrasound Renal Denervation System and on August 23, 2023 to discuss, make recommendations, and vote on information regarding the premarket approval application (PMA) Medtronic Symplicity Spyral Renal Denervation System, I may be considered for participation in the advisory committee meeting described above.

Type of Interest	Nature	Magnitude
I. Personal/Immediate Family		
None		
II. Other Imputed Interests		
Employer's grant	SGE's institution involved in sponsor's (Day1) and competitor's product study (Day 2)	\$50,001 - \$70,000 Outstanding amount owed to the institution is between \$0 - \$5,000

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

<u>/S/</u>

Signature

June 28, 2023 Date

U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov